Valuation: Kenvue Inc.

Market Cap 37.11B 33.24B 30.57B 27.7B 51.78B 3,524B 52.75B 365B 146B 1,853B 139B 136B 5,845B P/E 2026 *
20.6x
P/E 2027 * 17.8x
Enterprise Value 44.26B 39.64B 36.46B 33.04B 61.75B 4,202B 62.91B 435B 175B 2,211B 166B 163B 6,971B EV / Sales 2026 *
2.84x
EV / Sales 2027 * 2.74x
Free-Float
98.87%
Yield 2026 *
4.4%
Yield 2027 * 4.45%
1 day-1.28%
1 week-1.33%
1 month+12.14%
3 months+0.36%
6 months+10.79%
Current year+11.94%
1 week 19.2
Extreme 19.2
20
1 month 17.16
Extreme 17.165
20
Current year 16.56
Extreme 16.555
20.13
1 year 15.88
Extreme 15.88
20.13
3 years 14.02
Extreme 14.02
25.17
5 years 14.02
Extreme 14.02
27.8
10 years 14.02
Extreme 14.02
27.8
Manager TitleAgeSince
Chief Executive Officer 56 14/07/2025
Director of Finance/CFO 48 12/05/2026
Chief Tech/Sci/R&D Officer 57 -
Director TitleAgeSince
Chairman 70 01/05/2023
Director/Board Member 66 04/05/2023
Director/Board Member 59 08/05/2023
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 A Free

General Counsel

50,503 0.0026%
10/2/26 A Free

Chief Operating Officer

50,946 0.0027%
10/2/26 A Free

Chief Technology Officer

33,203 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%-1.33%+34.38%+2.28% 37.11B
+0.61%+0.34%+7.45%+7.99% 374B
+2.93%+0.15%+20.49%+10.06% 260B
+2.07%-1.36%-5.66%+11.39% 140B
+2.29%+1.33%+23.67%+27.17% 75.75B
+1.66%+0.94%+29.87% - 54.59B
+1.17%+3.85%-23.22%-24.05% 46.14B
+0.39%+0.52%+12.97%+4.52% 39.52B
-1.89%-2.01%-9.83%-9.65% 35.9B
+0.27%+0.16%+15.14%+35.30% 21.52B
Average +0.84%+0.05%+10.53%+7.22% 108.52B
Weighted average by Cap. +1.39%+0.12%+10.53%+8.57%

Financials

2026 *2027 *
Net sales 15.6B 13.97B 12.85B 11.64B 21.77B 1,481B 22.17B 153B 61.52B 779B 58.54B 57.3B 2,457B 15.97B 14.3B 13.16B 11.92B 22.28B 1,516B 22.7B 157B 62.98B 798B 59.94B 58.66B 2,516B
Net income 1.8B 1.61B 1.48B 1.34B 2.51B 171B 2.56B 17.68B 7.1B 89.88B 6.75B 6.61B 283B 2.09B 1.87B 1.72B 1.56B 2.92B 199B 2.97B 20.55B 8.25B 104B 7.85B 7.68B 329B
Net Debt 7.15B 6.4B 5.89B 5.34B 9.97B 679B 10.16B 70.23B 28.19B 357B 26.83B 26.26B 1,126B 6.57B 5.89B 5.42B 4.91B 9.17B 624B 9.34B 64.58B 25.93B 328B 24.67B 24.15B 1,035B
Projected Income Statement - Annual - Kenvue Inc.
Logo Kenvue Inc.
Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. Net sales break down by family of products as follows: - self care products (42,3%): for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - personal care products (30.3%): primarily oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.); - beauty and skin care products (27.4%): hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.). Product marketing is assured through direct sales, distributors and the Internet. Net sales are distributed geographically as follows: North America (49%), Europe-Middle East-Africa (23%), Asia-Pacific (19.3%) and Latin America (8.7%).
Employees
21,890
Date Price Change Volume
30/10/26 $19.31 -1.28% 66,596,317
29/10/26 $19.56 +1.19% 12,324,528
28/10/26 $19.33 -0.51% 10,645,933
27/10/26 $19.43 -0.36% 15,866,807
26/10/26 $19.50 -0.36% 9,541,801
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Kenvue Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
19.31USD
Average target price
19.50USD
Spread / Average Target
+0.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kenvue Inc.
  1. Stock Market
  2. Stocks
  3. KVUE Stock